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Genetic factors, as well as environmental factors, play a role in development of nasopharyngeal carcinoma (NPC). A number of
single nucleotide polymorphisms (SNPs) have been reported to be associated with NPC. To confirm these genetic associations with
NPC, two independent case-control studies from Southern China comprising 1166 NPC cases and 2340 controls were conducted.
Seven SNPs in ITGA9 at 3p21.3 and 9 SNPs within the 6p21.3 HLA region were genotyped. To explore the potential clinical
application of these genetic markers in NPC, we further evaluate the predictive/diagnostic role of significant SNPs by calculating
the area under the curve (AUC). Results. The reported associations between ITGA9 variants and NPC were not replicated. Multiple
loci of GABBR1, HLA-F, HLA-A, and HCG9 were statistically significant in both cohorts (𝑃combined range from 5.96 × 10−17 to 0.02).
We show for the first time that these factors influence NPC development independent of environmental risk factors. This study also
indicated that the SNP alone cannot serve as a predictive/diagnostic marker for NPC. Integrating the most significant SNP with IgA
antibodies status to EBV, which is presently used as screening/diagnostic marker for NPC in Chinese populations, did not improve
the AUC estimate for diagnosis of NPC.

1. Background
Nasopharyngeal carcinoma (NPC) is rare in most regions
of the world; however, it is a common cancer in Southern
China, especially in the Guangdong and Guangxi Provinces.
The incidence rate of NPC for males in the Southern Chinese
provinces of Guangdong and Guangxi is more than 20 per
100,000 person-years and up to 25–40 per 100,000 personyears in some areas bordering the Xijiang River and Pearl

River drainages in these two provinces [1, 2]. It has been
well established that Epstein-Barr virus (EBV) is strongly
associated with NPC [3–5]. The association of EBV antibodies
and NPC were first reported in 1966 [6]. Later, the presence
of IgA antibodies to EBV in serum was found to serve
as a predictive marker for NPC in Chinese populations
[7–9]. IgA antibody titers to the EBV viral capsid antigen
(EBV/IgA/VCA) and to the EBV early antigen (EBV/IgA/EA)
have been used for the screening and diagnosis of NPC
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for many years in Southern Chinese populations [7, 9–11].
Epidemiological studies have pointed to other environmental factors (including consumption of salt-preserved fish,
exposure to domestic wood-cooking fires, and exposure to
occupational solvents) as having a role in development of
NPC [5, 12].
Evidence for genetic modulation of NPC risk has accumulated recently. Familial aggregation of NPC cases has
been observed in both high- and low-risk populations in
different geographic regions [5, 13–15]. Several studies have
shown associations between HLA genes and NPC [16–21].
The results from our phase I cohort confirm and extend
previously reported HLA and NPC associations in Southern
Chinese populations [22]. Two genome-wide association
studies (GWAS) have identified multiple gene association
with risk of NPC in Chinese ancestry cohorts [23, 24].
The first GWAS comprised 111 unrelated NPC cases and
260 controls and a replication sample set of 168 cases and
252 controls from the Malaysian Chinese population [23]
reported evidence of association with ITGA9 on Chr 3p21.3121.2. The second GWAS was conducted in 277 Taiwanese
NPC cases and 285 controls and included two independent
replication sets. This group found associations with variants
on Chr 6p21.3 in or near HCG9, HLA-A, HLA-F, and GABBR1
genes [24].
To investigate whether genetic variants can improve the
EBV IgA antibodies test method for NPC diagnosis, we
extended previously reported GWAS associations with NPC
to Han Chinese from Southern China—the highest NPC
incidence region. Here, two independent case-control studies
were conducted—phase I cohort with 350 NPC cases and 619
controls and phase II cohort with 816 NPC cases and 1721
controls to determine if the polymorphisms of ITGA9, HLAA, HLA-F, GABBR1, and HCG9 were associated with NPC
development or can be potential genetic markers for onset of
NPC in a Southern Chinese population.

2. Materials and Methods
2.1. Cases and Controls (Table 1). The NPC cohorts were
recruited from areas along the Xijiang River in Guangdong
and Guangxi Provinces of Southern China in two collection
phases [5, 25]. Phase I participants were recruited from
April 2000 to June 2001. NPC cases were either incident or
prevalent biopsy-confirmed NPC cases. The controls were
the case’s spouse or geographically matched residents who
were NPC-free at the time of study enrollment. Phase II study
participants were recruited from November 2004 to October
2005. Cases were incident or prevalent, biopsy-confirmed
NPC. Controls were NPC-free at the time of study enrollment
and matched to NPC cases on age and district/township of
residence. NPC cases were patients at Wuzhou Red Cross
Hospital in Wuzhou City and outpatients at Cangwu Institute
for NPC Control and Prevention in Cangwu County. All
participants self-identified as Han Chinese and reported at
least three generations of residency in Guangdong or Guangxi
Province, China.
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IgA antibodies to EBV capsid antigen (EBV/IgA/VCA)
and IgA antibodies to EBV early antigen (EBV/IgA/EA)
were determined by serological testing at the time of study
enrollment. The cutoff titer for the seropositive status was
at least 1 : 10 and 1 : 5 for IgA/VCA and IgA/EA, respectively,
based on local standard. Blood samples were obtained from
350 NPC cases (66.6% male) and 619 controls (42.8% male)
for phase I; the mean age was 45 years ± 11 and 46 years ± 10
for NPC cases and controls, respectively. For phase II, blood
samples were collected from 816 NPC cases (73.2% male) and
1721 controls (61.4% male); the mean age was 45 years ± 11
and 46 years ± 12 for NPC cases and controls, respectively.
Family history of NPC, parental ancestry for three generations, dietary and smoking habits, household exposures to
wood fires, and occupational exposures to solvents were
also captured by questionnaire in the phase II cohort [5].
Participants were asked if there was a family history of NPC
in first- (children, siblings, or parents), second- (aunts or
uncles, nieces or nephews, and grandparents), or third-degree
relatives (first cousins). Information was also collected on the
frequency of consumption per month (≥3 times/month, and
<3 times/month) of salty fish and preserved meat. Questions
on cigarette smoking included current and past smoking
habits and number of cigarettes smoked per day. Questions
on household and occupational exposures captured data on
domestic exposure to wood fires for cooking and occupational exposures to solvents (e.g., formaldehyde, acetone,
toluene, or xylene) and duration of exposure (>10 years or
≤10 years). Responses were recorded by double-entry and
verification of all data was performed to avoid data entry
errors. We excluded persons of minority ethnicity and those
who had blood relatives in either the case or control group.
We also did not allow overlap in participation between phase
I and phase II; the cohorts were independent. Institutional
review board approval was obtained from all participating
institutions and informed consent was obtained from each
study participant.
2.2. Genomic DNA Extraction. In phase I participants, DNA
was extracted from whole blood or lymphoblastoid cell lines
using QIAamp DNA blood maxi kit (Qiagen, Valencia, CA,
catalog number 51194). More than 80% of the genotypes
were determined from DNA directly extracted from whole
blood. In phase II participants, DNA was extracted from
whole blood by traditional phenol/chloroform method with
Phase Lock Gel tube (Qiagen, MaXtract High Density, catalog
number 129065).
2.3. Genotyping. In both phases I and II, 7 SNPs of ITGA9
on 3p21.3 and 9 SNPs within the GABBR1, HLA-F, HLAA, and HCG9 genes on chromosome 6p21.3 were genotyped
by using commercially available TaqMan SNP genotyping
assays and GeneAmp PCR System 9700 (Applied Biosystems,
Foster City, CA, USA), in accordance with the manufacturer’s
instructions. The sequence detection software was used for
allelic discrimination. For quality control, 8 to 16 templatefree controls, one family sample [25], and 5% to 10% of
duplicate samples were included in each 384-well plate.
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Table 1: Characteristics of participants in a study of nasopharyngeal carcinoma (NPC) in southern China.
Phase I
Cases
45 ± 11.4 (SD)
66.6 (233/350)
95.4 (334/350)
59.5 (201/348)
350

Age (years)
Male, %
IgA/VCA+∗ , %
IgA/EA+∗∗ , %
Total

Phase II
Controls
46 ± 9.7 (SD)
42.8 (265/619)
44.7 (277/619)
2.3 (14/619)
619

Cases
45 ± 11.0 (SD)
73.2 (597/816)
95.8 (782/816)
72.4 (591/816)
816

Controls
46 ± 11.7 (SD)
61.4 (1056/1721)
42.3 (731/1721)
2.6 (44/1721)
1721

Age: the age at diagnosis of NPC for cases and age of enrollment for controls.
SD: standard deviation.
∗
Positive for IgA antibodies to Epstein-Barr virus capsid antigen.
∗∗
Positive for IgA antibodies to Epstein-Barr virus early antigen.
The cutoff value for seropositive status is 1 : 10 for IgA/VCA and 1 : 5 for IgA/EA.

Table 2: Association between alleles of SNPs at 6p21.3 and NPC in phase I and phase II combined.
Gene-SNP
GABBR1-rs2267633
GABBR1-rs29230
GABBR1-rs29232
HLA-F-rs3129055
HLA-A-rs2517713
HCG9-rs9260734
HCG9-rs3869062
HCG9-rs5009448
HCG9-rs16896923

Risk allele
A
T
A
G
T
G
A
C
T

Phase I and phase II
OR (95% CI)∗
𝑃∗
1.61 (1.41–1.84)
1.02𝐸 − 12
1.64 (1.45–1.89)
1.36𝐸 − 13
1.35 (1.21–1.49)
1.85𝐸 − 08
1.14 (1.02–1.28)
0.02
1.61 (1.43–1.82)
2.44𝐸 − 16
1.67 (1.47–1.87)
5.96𝐸 − 17
1.60 (1.42–1.81)
3.4𝐸 − 14
1.62 (1.45–1.82)
1.89𝐸 − 16
1.54 (1.35–1.75)
4.56𝐸 − 11

Phase I and phase II
OR (95% CI)∗∗
𝑃∗∗
1.48 (1.17–1.87)
0.001
1.61 (1.28–2.04)
6.14𝐸 − 05
1.41 (1.16–1.71)
0.0006
1.33 (1.09–1.64)
0.008
1.69 (1.35–2.08)
2.58𝐸 − 06
1.75 (1.41–2.17)
6.48𝐸 − 07
1.63 (1.30–2.04)
1.97𝐸 − 05
1.66 (1.33–2.06)
3.46𝐸 − 06
1.69 (1.33–2.13)
2.19𝐸 − 05

Phase II
OR (95% CI)∗∗∗
1.41 (1.02–1.95)
1.61 (1.16–2.22)
1.33 (1.01–1.76)
1.47 (1.10–1.20)
1.64 (1.20–2.22)
1.75 (1.28–2.44)
1.60 (1.16–2.19)
1.64 (1.20–2.26)
1.64 (1.18–2.27)

𝑃∗∗∗
0.03
0.004
0.05
0.01
0.003
0.0005
0.004
0.002
0.005

OR: odds ratio. CI: confidence interval.
∗
Adjusted for sex and age.
∗∗
Additionally adjusted for EBV/IgA/VCA and EBV/IgA/EA titers.
∗∗∗
Additionally adjusted for EBV/IgA/VCA and EBV/IgA/EA antibody titers and other environmental factors including family history with NPC, consumption
of salt-preserved fish, exposure to domestic wood cooking fires, and exposure to occupational solvents.

2.4. Statistical Analysis. Hardy-Weinberg equilibrium (HWE)
assumptions were independently tested for each SNP in
cases and controls for each phase group as well as the
two phases combined as a quality control measure. For
allele association (Table 2, Supplementary Tables 1 and 2;
Supplementary Material available online at http://dx.doi.org/
10.1155/2014/434072), the Armitage’s trend test was used
to calculate the 𝑃 value for additive allele effects on the
disease penetrance. ORs were calculated by Mantel-Haenszel
estimate based on contingency tables of allele-by-trait counts.
For controlling the confounding covariates (age, sex, etc.),
the stratified case-control test was performed. All results
shown were adjusted for age and sex. In order to exclude the
influence of EBV, we analyzed the associations between polymorphisms and the occurrence of NPC using EBV/IgA/VCA
and EBV/IgA/EA antibody titers as covariates. For phase II,
environmental factors including family history with NPC,
consumption of salt-preserved fish, exposure to domestic
wood-cooking fires, and exposure to occupational solvents
were used as covariates. The receiver operator characteristic
(ROC) curve was used to assess the diagnostic performance
of EBV/IgA/VCA or EBV/IgA/EA alone, SNP alone, and the
integration of these risk factors. Statistics were calculated in
the statistical package SAS and SAS Genetics version 9.1.3.

Linkage disequilibrium (LD) maps, blocks, and haplotypes
were generated by Haploview software [26].

3. Results
3.1. Association Results with SNPs on HLA Region at 6p21.3.
As shown in Table 1, over 95% of NPC cases (titer 1 : 10 to
1 : 640) and 42%–45% of the controls (titer 1 : 10 to 1 : 160)
were positive for EBV/IgA/VCA antibodies; about 60%–
72% of NPC cases (titer 1 : 5 to 1 : 640) and 2%-3% of the
controls (titer 1 : 5 to 1 : 80) were positive for EBV/IgA/EA
antibodies in the two cohorts. EBV/IgA/EA positive serostatus was always concordant with IgA/VCA seropositive status.
To replicate the results of the GWAS showing association
between NPC and chromosome 6 [24], 9 SNPs within the
HLA region previously found to be associated with NPC
were genotyped (Table 2). The genotype frequencies for
9 polymorphisms conformed HWE expectations for two
control groups; the call rate was 97.9%–99.3% for the 9 SNPs.
Table 2 provides the risk alleles, the OR, 95% confidence
intervals (CIs), and 𝑃 values for phases I and II combined and
phase II controlling for environmental factors. Eight SNPs
in GABBR1, HLA-A, and HCG9 were significantly associated
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rs5009448

rs16896923

HCG9

rs3869062

rs2517713

rs29232

HLA-A

rs9260734

HLA-G

rs3129055

HLA-F

rs29230

rs2267633

GABBR1

Table 3: The diagnosis performance of IgA/VCA and IgA/EA and
genetic signature.
Test
Sensitivity (%) Specificity (%) Accuracy (%)
EBV/IgA/VCA
95.7
56.9
69.8
EBV/IgA/EA
68.6
97.5
87.9
HCG9-rs9260734
95.6
9.3
38.0
Note: the threshold for IgA/VCA is 1 : 10 and for IgA/EA is 1 : 5.
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Figure 1: LD map based on 𝐷 was drawn using the genotype of the
cases and controls.

with NPC in the phase I cohort (Supplementary Table 1:
𝑃 = 0.0001–0.02), phase II cohort (Supplementary Table
1: 𝑃 = 3.09 × 10−12 –1.13 × 10−6 ), and combined phases I
and II (Table 2: 𝑃 = 5.96 × 10−17 –1.85 × 10−8 ). The SNP
on HLA-F was significant in phase II and in the combined
cohort but not in the smaller phase I cohort, although the
ORs were in the same direction. After additionally controlling
for EBV/IgA/VCA and EBV/IgA/EA antibody titers, 9 SNPs
were also significant (Table 2). For the phase II cohort, after
adjusting for sex, age, and EBV antibodies titers, we further
controlled for environmental factors, which were shown
to be associated with NPC in this cohort [5], including
family history with NPC, consumption of salt-preserved fish,
exposure to domestic wood-cooking fires, and exposure to
occupational solvents as covariates. The 9 SNPs remained
significantly associated with the risk of NPC (Table 2, last two
columns).
Based on the LD map all 9 SNPs are in the same block
(Figure 1). The HCG9-rs9260734, the most significant SNP,
was used for evaluating whether the genetic signature can
serve as a diagnostic marker for NPC. Table 3 presented
the sensitivity, specificity, and accuracy for EBV/IgA/VCA,
EBV/IgA/EA, and SNP test. The specificity (9.3%) and accuracy (38%) of HCG9-rs9260734 are lower than 50%, which
indicated that the SNP does not qualify as a diagnostic
marker. To evaluate if the SNP can improve current IgA
antibodies test for NPC diagnosis, we compared the receiver
operating characteristic (ROC) curves between IgA/VCA or
IgA/EA alone and integrated the SNP with status of IgA/VCA
or IgA/EA. The area under the curve (AUC) for integrated
markers did improve compared with IgA/VCA or IgA/EA
alone (0.917 versus 0.915 for IgA/VCA; 0.833 versus 0.839
for IgA/EA; Figures 2(a) and 2(b)); however, this was not
statistically significantly different.

3.2. Association Results with SNPs on ITGA9 at 3p21.3. To
examine the influence of ITGA9 gene variants on NPC [23],
7 SNPs in ITGA9 were genotyped in phase I and phase II
cohorts. Each of the 7 SNPs confirmed to HWE expectations
in controls for both cohorts and the genotype call rate was
96.8%–99.4%. No evidence of association was seen between
6 of the SNPs and NPC in phase I or phase II or in the
combined analysis (Supplementary Tables 1 and 2). SNP
(rs169111) was modestly significant in the combined analysis
(Supplementary Table 2: OR = 1.4, 𝑃 = 0.03) but not after
adjusting for EBV IgA antibodies titers.

4. Discussion
In our study, we have demonstrated the strong associations
of 9 SNPs located within GABBR1, HLA-F, HLA-A, and
HCG9 with NPC. Our results, from two independent Han
Chinese NPC cohorts, confirm the previous associations
and effect sizes reported in the Taiwanese GWAS [24]. The
etiology of nasopharyngeal carcinoma is influenced by both
genetic and environmental factors. EBV IgA antibody status
is a strong predictive marker and plays an important role
in NPC development in Southern Chinese populations [9,
10, 27, 28]. Our results show that over 95% of NPC cases
were EBV/IgA/VCA antibody positive and about 60%–72%
of NPC cases were positive for EBV/IgA/EA antibodies.
To exclude potential influence of EBV antibody status, we
controlled EBV/IgA/VCA and EBV/IgA/EA antibody titers
during the analysis. The results indicated that the variants
of GABBR1, HLA-F, HLA-A, and HCG9 were still associated
with NPC. In a previous study we reported that family history
with NPC, consumption of salt-preserved fish, exposure to
domestic wood-cooking fires, and exposure to occupational
solvents were risk factors of NPC [5]. These environmental
exposure data were available in our phase II cohort. When
we adjusted for these factors in our association analysis, the
95% confidence intervals overlapped indicating that variants
on GABBR1, HLA-F, HLA-A, and HCG9 association were
independent of environmental factors with NPC onset; the
reduced statistical significance in the analysis adjusted for
environmental factors reflects the small sample size with
environmental data. These results, from two independent
cohorts, affirm the associations of GABBR1, HLA-F, HLA-A,
and HCG9 with NPC in the Han Chinese population. HLAA and HCG9 have been reported to be associated with EBVpositive Hodgkin lymphoma and infectious mononucleosis
caused by EBV infection [29, 30]. This suggested that genetic
variation chromosome 6p21.3 can influence the outcome of
primary EBV infection and the level of viral persistence.
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Figure 2: ROC curves.

A genome-wide expression profiling has revealed that
increased EBV gene expression is strongly associated with
inhibition of multiple HLA class I gene expression in NPC
[31], further implicating these genes with NPC.
EBV/IgA/VCA and EBV/IgA/EA antibody titers, especially EBV/IgA/VCA, have been used for the screening and
diagnosis of NPC for over 30 years in Southern Chinese
populations [7, 9–11]. Along with the cancer genetic/genomic
project development, new genetic variants associated with
NPC are continuously being discovered. There is a growing
need to evaluate the genetic markers for medical practice.
Our interest is whether the significant SNPs can serve as a
diagnostic marker or improve the IgA antibodies test for NPC
prediction. Sensitivity, specificity, and accuracy are widely
used statistics to quantify how good and reliable a test is.
The receiver operating characteristic (ROC) curve is a graphic
presentation of the relationship between both sensitivity
and specificity and becomes the standard analytical tool
for evaluating diagnostic tests. In this study, the specificity
and accuracy of SNP was lower than 50%; the AUC of
SNP was less than 0.6 indicating SNP alone cannot be a
diagnostic marker for NPC. Considering the positive rate
for EBV/IgA/VCA antibodies in the general population is
about 3% [10], we randomly selected samples and made
the control group that contained 3% IgA/VCA positive,
then we repeated the ROC analysis; we obtained similar
results. The AUC increased when IgA/VCA or IgA/EA was
integrated with SNP; however, the effect was not statistically
significant. To our knowledge, this is the first study to

explore and incorporate the genetic variants to clinical use
for NPC. Our results show that there is a strong association
between variants of GABBR1, HLA-F, HLA-A, and HCG9
and NPC, but they cannot be useful for individualized risk
prediction/diagnosis of NPC. However, risk profile based on
a combination of genetic and other risk factors leads to an
appreciable increased risk of disease and there is potential for
increased predictive power as more genetic risk variants are
detected [32].
We were unable to confirm the reported association
with NPC of 7 SNPs in ITGA9 in our large Chinese Han
population (𝑁 = 3506) from an NPC high incidence region
of Southern China, although this study was well powered to
detect a similar level of association. Based on our results, the
minor allele frequencies (MAFs) for these 7 SNPs were lower
(between 0.024 and 0.03). The previous study was carried out
on a relatively small sample with 279 cases and 512 controls
[23]; the few patients and a low MAF may have contributed to
low statistical power for SNP association. However, two more
recent NPC GWAS also failed to replicate the association of
ITGA9 with NPC [33, 34].
Our study is unique in that two critical EBV antibody
titers, as well as environmental factors, are available for
inclusion in the statistical modeling. We controlled for these
risk factors to determine the genetic association with NPC.
This study systematically replicates the association from two
NPC GWAS [23, 24] performed in NPC high-risk Asian
populations. We also explored potential clinical use for
significant genetic makers. Further study should focus on
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how these genetic variants impact function at the molecular
and cellular levels to affect NPC development. Understanding
the functional consequences of genetic variation will be
critical to advancing our knowledge of the etiology of the
disease and implementing rational medical strategies.

5. Conclusion
In summary, our results extend the association of the
GABBR1, HLA-F, HLA-A, and HCG9 locus with NPC to
the Han Chinese population of Southern China. We show
for the first time that these factors are independent of
environmental risk factors previously shown to influence
NPC development. This study also indicated that EBV IgA
antibodies in combination with these genetic makers may not
be useful for diagnostic prognosis of NPC.
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